Amgen reported strong third-quarter financial results, with sales up 11% and EPS up 16%, and raised full-year guidance. The successful integration of Onyx Pharmaceuticals and positive developments in their pipeline, including upcoming data releases, signal continued growth. These factors are likely to generate positive market sentiment and boost the stock price in the short term.
[1]